Meta-analysis of anti-ribosomal P antibodies in lupus psychosis

Table 2 Effect of anti-ribosomal P antibody status on psychosis risk

Study	Total (N)	Meanage (yr)	Female (%)	Mean illness duration (yr)	aRP(+) (n)	aRP(-) (n)	Psychosis (n)	Psychosis a-nd aRP(+) (n)	No psycho-sis and aRP(+) (n)	Psychosis and aRP(-) (n)	No psycho-sis and aRP(-) (n)	OR	95%CI
Abdel-Nesser 2008	32	25.0	87.5	3.9	7	25	1	1	6	0	25	8.33	0.25-278.68
Arnett 1996	364				63	301	17	8	55	9	292	4.72	1.74-12.76
Briani 2009	219	28.0	84.5		45	174	1	1	44	0	174	7.91	0.26-239.58
Caponi 2002	149	37.1	93.3	9.3	18	131	1	0	18	1	130	0.07	0-2.6 × 107
Haddouk 2009	200	30.5	86.5		47	153	3	1	46	2	151	1.64	0.15-18.51
Hanly 2008	214	34.9	87.4	0.4	17	197	7	3	14	4	193	10.34	2.10-50.82
Hanly 2011	991	35.2	89.1	0.5	91	900	14	4	87	10	890	4.09	1.26-13.32
Isshi 1996	75				21	54	19	10	11	9	45	4.55	1.49-13.88
Massardo 2002	141	33.0	90.1	5.0	21	120	2	2	19	0	120	25.26	1.10-581.69
Nojima 1992	91		80.0		38	53	10	9	29	1	53	16.45	1.98-136.36
Press 1996	79				16	63	13	5	11	8	55	3.13	0.86-11.37
Schneebaum 1991	269				51	218	29	13	38	16	202	4.32	1.92-9.71
Shovman 2006	44				6	38	1	1	5	0	38	15.2	0.45-513.80
The 1992	116				18	98	13	3	15	10	88	1.76	0.43-7.15
Van Dam 1991	38				12	26	1	1	11	0	26	4.73	0.15-151.50
Yoshio 1995	70	31.9	94.3		41	29	10	3	38	7	22	0.25	0.06-1.06
Total	3093				512	2581	142	65	447	77	2504

aRP: Anti-ribosomal P; OR: Odds ratios; CI: Confidence interval.